Compare LODE & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | ANIK |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | 45 | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 200.9M |
| IPO Year | 2004 | 1996 |
| Metric | LODE | ANIK |
|---|---|---|
| Price | $2.27 | $19.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.2M | 59.8K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.55 | ★ 80.16 |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $112,819,000.00 |
| Revenue This Year | $303.79 | $7.82 |
| Revenue Next Year | $410.04 | $5.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.23 | $8.67 |
| 52 Week High | $4.98 | $22.88 |
| Indicator | LODE | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 27.65 | 38.33 |
| Support Level | N/A | $13.88 |
| Resistance Level | $3.61 | $22.70 |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 17.21 | 6.76 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.